The overexpression of Bcl-2 is particularly evident in leukemias, lymphomas, especially follicular lymphoma (FL) and chronic lymphocytic leukemia CLL), as well as in some solid tumors, such as breast cancer, lung cancer, and melanoma [98,99]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.